Asset icon - trade crypto, stocks, and gold on Pluang
Trade on Pluang
One platform for all markets
Download

Burberry sees 2% sales growth with strong gains in Americas and China, marking a key fiscal year turnaround.

Company Fundamentals
14 May 2026
CNBC
View Source
Bullish
pluang ai news

Burberry reported a 2% increase in comparable sales for the fiscal year, driven by a 10% sales growth in the Americas and China during the quarter ending in March. The British luxury brand described the year as a "meaningful inflection point," with full-year revenue steady at £2.4 billion. CEO Joshua Schulman highlighted the return to profitable sales growth and expressed confidence in ongoing strategy and future growth opportunities. This performance signals a positive turnaround for Burberry, especially in key markets like Greater China and the Americas.

More News

Pension officials criticize SpaceX's IPO structure as overly favorable to Elon Musk's control.

Pension officials criticize SpaceX's IPO structure as overly favorable to Elon Musk's control.

Top pension officials from New York and California have expressed concerns about SpaceX's upcoming IPO, criticizing its dual-class share structure that grants Elon Musk significant voting power and control. They warn that this 'most management-favora...

Market News
Bearish
40 minutes ago
Ipsen presents corabotase, a novel neuro-inhibitor, showing promising phase II results for facial wrinkle treatment.

Ipsen presents corabotase, a novel neuro-inhibitor, showing promising phase II results for facial wrinkle treatment.

Ipsen has introduced corabotase, the first molecule in a new class of recombinant neuro-inhibitors, at the SCALE symposium. Phase II trial data show corabotase's safety and efficacy in treating moderate to severe facial wrinkles, including glabellar ...

Market News
Bullish
2 hours ago
Ipsen unveils corabotase, a novel neuroinhibitor, showing promising Phase II results for facial line treatment.

Ipsen unveils corabotase, a novel neuroinhibitor, showing promising Phase II results for facial line treatment.

Ipsen has introduced corabotase, the first molecule in a new class of recombinant neuroinhibitors, designed to treat moderate to severe upper facial lines such as glabellar lines. Phase II trial data presented at the SCALE Symposium showed corabotase...

Others
Bullish
2 hours ago
Bitcoin falls below $80K amid inflation fears and China-US tensions over Taiwan

Bitcoin falls below $80K amid inflation fears and China-US tensions over Taiwan

Bitcoin dropped to $79,200, breaking the key $80,000 support level amid rising inflation and geopolitical tensions between the US and China over Taiwan. Solana and other major cryptocurrencies also declined, while Dogecoin was the only gainer. Inflat...

Market News
Bearish
4 hours ago
Forward Industries reports $585.6M Q1 loss due to Solana price drop despite higher staking revenue

Forward Industries reports $585.6M Q1 loss due to Solana price drop despite higher staking revenue

Forward Industries, the largest Solana treasury company, posted a $585.6 million net loss in Q1 2026, mainly from a $560.2 million digital asset markdown and a $33 million impairment on its Solana holdings. The company holds nearly 7 million SOL toke...

Protocol Fundamentals
Bearish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App